



HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS S.A.

CNPJ 05.197.443/0001-38

NIRE 233.000.392-71

MATERIAL FACT

**FINANCIAL STATEMENTS 2024, 2023 and 2022
AND
SUS REIMBURSEMENTS AND ANS FINES AGREEMENT**

Hapvida Participações e Investimentos S.A. (B3: HAPV3 – Company), in compliance with current regulations, hereby informs its shareholders and the market in general as follows:


Consistent with the practice adopted in recent quarters, the Company has disclosed today on its investor relations website:

- i. Financial statements for the year ended December 31, 2024, prepared in compliance with IFRS 17 – CPC 50 (FS 2024 – CPC 50); and
- ii. Financial statements for the year ended December 31, 2024, prepared in compliance with IFRS 4 – CPC 11, voluntarily disclosed and serving as the basis for the preparation of the Company's earnings presentation and release (FS 2024 – CPC 11 and, along with FS 2024 – CPC 50, are FS 2024).

Furthermore, the Company states that its management has proactively identified the need to restate accounting balances for the fiscal years 2016 to 2023 and has informed its independent auditor appropriately. Accordingly, in compliance with IAS 8 – CPC 23, the Company (a) retrospectively restated the amounts related to the fiscal year ended December 31, 2023, whose corrected balances are presented in the 2024 financial statements for comparative purposes, and (b) restated the opening balances of assets, liabilities, and shareholders' equity for the 2023 fiscal year, which already include adjustments related to previous years (*i.e.*, 2016 to 2022).

Such restatements resulted from (i) write-off of deferred tax liabilities and related tax effects, mostly concentrated in the NDI vertical, (ii) write-off of assets and liabilities with no expectation of realization, mainly related to the derecognition of an indemnifiable asset in the context of an arbitration in the NDI vertical, which had not been properly accounted for in the opening balance sheet, (iii) extemporaneous write-off of blockages and judicial deposits (2016-2023), (iv) adjustments related to the monetary inflation of certain assets and liabilities and (v) recognition of deferred revenue from IFRS17 insurance contracts, with an impact exclusively on FS 2024 – CPC 50.

The following chart presents the consolidated effects of the adjustments:




Further details on the adjustments can be found in the 2024 Financial Statements, specifically in note 2.6 in the notes to financials and in the Statement of Changes in Shareholders' Equity. On a consolidated basis, the adjustments mentioned above had an impact of +R\$503 million on the Company's shareholders' equity in the FS 2024 – CPC 50, representing a positive variation of 1.0% in shareholders' equity. With respect to the FS 2024 – CPC 11, the restatements totaled -R\$202 million, representing a negative variation of 0.4% in the Company's shareholders' equity.

Further on this matter, the Company clarifies that it has implemented and continues to implement a series of measures to strengthen its controls. Its financial statements for the fiscal year ended December 31, 2024, which include the adjustments mentioned above, received an unqualified opinion from PricewaterhouseCoopers Auditores Independentes Ltda. (PwC) and were also unanimously approved, without qualifications, by the members of its Statutory Audit, Risk, and Internal Controls Committee, Fiscal Council, and Board of Directors.

Additionally, in December 2024, the Company entered into a partial settlement agreement for amounts related to SUS Reimbursements (ReSUS) and ANS fines, under the framework of Law 14,973, dated September 16, 2024, regulated by Normative Ordinance of the Office of the Attorney General (AGU) #150, dated October 3, 2024. The terms proposed in the agreement, mediated by the Brazilian Attorney General's Office (AGU in Portuguese), enabled a significant reduction in disputed amounts that could potentially become subject to litigation. As such, liabilities of R\$2.9 billion were settled for R\$1.7 billion, resulting in a

net impact of R\$470 million on our results, broken down into R\$145 million in EBITDA and R\$325 million in financial results, as illustrated below:



On the positive side, there was a net reversal/discount of R\$866 million in SUS Reimbursements charges through December 2024 on a liability of R\$2.2 billion. The reversal was allocated as follows: R\$541 million in SUS Provisions under Costs and R\$325 million in the reversal of fines and interest under Financial Results.

On the other hand, there was a net recognition of R\$250 million in contingent liabilities related to ANS fines and R\$128 million of excess of balances of judicial deposits withdrawal by the Federal Government, without the possibility of being used in other proceedings or entities within the group, following all SUS Reimbursements reversals, as required by the regulation underpinning the agreement. From a cash flow perspective, an amount of R\$187 million is expected to be settled, with disbursement anticipated in the first half of 2025, an amount already provisioned.

The agreement's exhaustion is still subject to pending internal and operational procedures by ANS and AGU. However, these do not have the power to materially modify the conditions that governed the presentation of adhesions.

São Paulo/SP, March 19, 2025.

Luccas Augusto Adib
Chief Financial and Investor Relations Officer